Transações de insiders

EDGAR

Taysha Gene Therapies, Inc.

Transações informadas por diretores, executivos e detentores de mais de 10 % nos Formulários 3, 4 e 5 da SEC, lidas do XML de cada documento. Os códigos e sua redação são os da SEC.

O Formulário 4 deve ser entregue em até dois dias úteis após a transação; as mais recentes podem ainda não ter sido registradas.

Janela: transações datadas de 16 de nov. de 2025 em diante.

Compras no mercado aberto (código P)
0 transações, — ações
Vendas no mercado aberto (código S)
12 transações, 1.368.795 ações
Soma de ações × preço por ação: 6.658.093,26

Os totais somam as transações listadas; contam o que foi informado e não medem uma direção.

Exibindo 1–38 de 38

Transações de insiders, mais recentes primeiro, conforme os Formulários 3, 4 e 5 da SEC
DataDeclaranteCódigoAdquirido ou alienadoAçõesPreço por ação, conforme entregueValor (derivado)Ações detidas depoisDireta ou indiretaCaixa da Regra 10b5-1NotasFonte
10 de jul. de 2026 Protocolado em 10 de jul. de 2026Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Alienado (D)200.0006,24
1.248.000

Derivado: ações × preço por ação. Valor exato 1248000.00.

936.410Direta (D) Sim
F1, F2
  • F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.99 to $6.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Abrir documento 0001665124-26-000013 Lido do XML do documento Contestar esta linha
1 de jun. de 2026 Protocolado em 2 de jun. de 2026Long Alison S Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)21.3350—127.178Direta (D) Não
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir documento 0001891712-26-000002 Lido do XML do documento Contestar esta linha
1 de jun. de 2026 Protocolado em 2 de jun. de 2026Long Alison S Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor mobiliário derivativo: Stock Option (right to buy) — subjacente Common Stock (42.671) — preço de exercício 5.97
Adquirido (A)42.6710—42.671Direta (D) Não
F2
  • F2 The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir documento 0001891712-26-000002 Lido do XML do documento Contestar esta linha
1 de jun. de 2026 Protocolado em 2 de jun. de 2026Sepp-Lorenzino Laura Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)21.3350—127.178Direta (D) Não
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir documento 0001777421-26-000005 Lido do XML do documento Contestar esta linha
1 de jun. de 2026 Protocolado em 2 de jun. de 2026Sepp-Lorenzino Laura Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor mobiliário derivativo: Stock Option (right to buy) — subjacente Common Stock (42.671) — preço de exercício 5.97
Adquirido (A)42.6710—42.671Direta (D) Não
F2
  • F2 The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir documento 0001777421-26-000005 Lido do XML do documento Contestar esta linha
1 de jun. de 2026 Protocolado em 2 de jun. de 2026Donenberg Phillip B. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)21.3350—241.289Direta (D) Não
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir documento 0001238120-26-000008 Lido do XML do documento Contestar esta linha
1 de jun. de 2026 Protocolado em 2 de jun. de 2026Donenberg Phillip B. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor mobiliário derivativo: Stock Option (right to buy) — subjacente Common Stock (42.671) — preço de exercício 5.97
Adquirido (A)42.6710—42.671Direta (D) Não
F2
  • F2 The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir documento 0001238120-26-000008 Lido do XML do documento Contestar esta linha
1 de jun. de 2026 Protocolado em 2 de jun. de 2026Stalfort John A III Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)21.3350—1.176.559Direta (D) Não
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir documento 0001709418-26-000002 Lido do XML do documento Contestar esta linha
1 de jun. de 2026 Protocolado em 2 de jun. de 2026Stalfort John A III Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor mobiliário derivativo: Stock Option (right to buy) — subjacente Common Stock (42.671) — preço de exercício 5.97
Adquirido (A)42.6710—42.671Direta (D) Não
F3
  • F3 The shares vest on the earlier of June 1, 2027 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
Abrir documento 0001709418-26-000002 Lido do XML do documento Contestar esta linha
10 de abr. de 2026 Protocolado em 13 de abr. de 2026Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Adquirido (A)19.0211,71
32.525,91

Derivado: ações × preço por ação. Valor exato 32525.91.

1.336.410Direta (D) Sim— Abrir documento 0001665124-26-000011 Lido do XML do documento Contestar esta linha
10 de abr. de 2026 Protocolado em 13 de abr. de 2026Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Alienado (D)200.0004,46
892.000

Derivado: ações × preço por ação. Valor exato 892000.00.

1.136.410Direta (D) Sim
F1, F2
  • F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.335 to $4.625 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Abrir documento 0001665124-26-000011 Lido do XML do documento Contestar esta linha
10 de abr. de 2026 Protocolado em 13 de abr. de 2026Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Valor mobiliário derivativo: Employee Stock Option (right to buy) — subjacente Common Stock (19.021) — preço de exercício 1.71
Alienado (D)19.0210—455.920Direta (D) Sim
F3
  • F3 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir documento 0001665124-26-000011 Lido do XML do documento Contestar esta linha
4 de fev. de 2026 Protocolado em 6 de fev. de 2026Alam Kamran Officer: CHIEF FINANCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Alienado (D)1.6554,52
7.480,6

Derivado: ações × preço por ação. Valor exato 7480.60.

1.442.131Direta (D) Não
F1
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
Abrir documento 0001793412-26-000012 Lido do XML do documento Contestar esta linha
26 de jan. de 2026 Protocolado em 27 de jan. de 2026Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Alienado (D)26.9184,61
124.091,98

Derivado: ações × preço por ação. Valor exato 124091.98.

1.317.389Direta (D) Não
F1, F3
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.
Abrir documento 0001665124-26-000008 Lido do XML do documento Contestar esta linha
26 de jan. de 2026 Protocolado em 27 de jan. de 2026Nolan Sean P. Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Alienado (D)41.3124,61
190.448,32

Derivado: ações × preço por ação. Valor exato 190448.32.

2.908.257Direta (D) Não
F1, F3
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.
Abrir documento 0001569926-26-000008 Lido do XML do documento Contestar esta linha
26 de jan. de 2026 Protocolado em 27 de jan. de 2026Alam Kamran Officer: CHIEF FINANCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Alienado (D)23.8494,61
109.943,89

Derivado: ações × preço por ação. Valor exato 109943.89.

1.443.786Direta (D) Não
F1, F3
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.505 to $4.715 inclusive.
Abrir documento 0001793412-26-000008 Lido do XML do documento Contestar esta linha
23 de jan. de 2026 Protocolado em 27 de jan. de 2026Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Alienado (D)89.1324,75
423.377

Derivado: ações × preço por ação. Valor exato 423377.00.

1.344.307Direta (D) Não
F1, F2
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
Abrir documento 0001665124-26-000008 Lido do XML do documento Contestar esta linha
23 de jan. de 2026 Protocolado em 27 de jan. de 2026Nolan Sean P. Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Alienado (D)136.7894,75
649.747,75

Derivado: ações × preço por ação. Valor exato 649747.75.

2.949.569Direta (D) Não
F1, F2
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
Abrir documento 0001569926-26-000008 Lido do XML do documento Contestar esta linha
23 de jan. de 2026 Protocolado em 27 de jan. de 2026Alam Kamran Officer: CHIEF FINANCIAL OFFICER
S

Open market or private sale of non-derivative or derivative security

Common Stock
Alienado (D)78.9684,75
375.098

Derivado: ações × preço por ação. Valor exato 375098.00.

1.467.635Direta (D) Não
F1, F2
  • F1 The Reporting Person is selling the securities set forth herein pursuant to a mandatory sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.635 to $4.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
Abrir documento 0001793412-26-000008 Lido do XML do documento Contestar esta linha
12 de jan. de 2026 Protocolado em 14 de jan. de 2026Nolan Sean P. Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)1.008.0000—3.086.358Direta (D) Não
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir documento 0001569926-26-000002 Lido do XML do documento Contestar esta linha
12 de jan. de 2026 Protocolado em 14 de jan. de 2026Nolan Sean P. Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor mobiliário derivativo: Employee Stock Option (right to buy) — subjacente Common Stock (648.000) — preço de exercício 4.86
Adquirido (A)648.0000—648.000Direta (D) Não
F3
  • F3 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir documento 0001569926-26-000002 Lido do XML do documento Contestar esta linha
12 de jan. de 2026 Protocolado em 14 de jan. de 2026Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Adquirido (A)111.3240,6989
77.804,3436

Derivado: ações × preço por ação. Valor exato 77804.3436.

1.117.763Direta (D) Sim— Abrir documento 0001665124-26-000002 Lido do XML do documento Contestar esta linha
12 de jan. de 2026 Protocolado em 14 de jan. de 2026Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Adquirido (A)88.6761,71
151.635,96

Derivado: ações × preço por ação. Valor exato 151635.96.

1.206.439Direta (D) Sim— Abrir documento 0001665124-26-000002 Lido do XML do documento Contestar esta linha
12 de jan. de 2026 Protocolado em 14 de jan. de 2026Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Alienado (D)200.0004,71
942.000

Derivado: ações × preço por ação. Valor exato 942000.00.

1.006.439Direta (D) Sim
F1, F2
  • F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Abrir documento 0001665124-26-000002 Lido do XML do documento Contestar esta linha
12 de jan. de 2026 Protocolado em 14 de jan. de 2026Nagendran Sukumar Director · Officer: President and Head of RD
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)427.0000—1.433.439Direta (D) Sim
F3
  • F3 Represents a restricted stock unit (RSU) award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir documento 0001665124-26-000002 Lido do XML do documento Contestar esta linha
12 de jan. de 2026 Protocolado em 14 de jan. de 2026Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Valor mobiliário derivativo: Employee Stock Option (right to buy) — subjacente Common Stock (111.324) — preço de exercício 0.6989
Alienado (D)111.3240—111.359Direta (D) Sim
F4
  • F4 The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir documento 0001665124-26-000002 Lido do XML do documento Contestar esta linha
12 de jan. de 2026 Protocolado em 14 de jan. de 2026Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Valor mobiliário derivativo: Employee Stock Option (right to buy) — subjacente Common Stock (88.676) — preço de exercício 1.71
Alienado (D)88.6760—474.941Direta (D) Sim
F5
  • F5 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir documento 0001665124-26-000002 Lido do XML do documento Contestar esta linha
12 de jan. de 2026 Protocolado em 14 de jan. de 2026Nagendran Sukumar Director · Officer: President and Head of RD
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor mobiliário derivativo: Employee Stock Option (right to buy) — subjacente Common Stock (274.000) — preço de exercício 4.86
Adquirido (A)274.0000—274.000Direta (D) Sim
F6
  • F6 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir documento 0001665124-26-000002 Lido do XML do documento Contestar esta linha
12 de jan. de 2026 Protocolado em 14 de jan. de 2026Alam Kamran Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Adquirido (A)359.0000—1.546.603Direta (D) Não
F1
  • F1 Represents a restricted stock unit (RSU) award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir documento 0001793412-26-000002 Lido do XML do documento Contestar esta linha
12 de jan. de 2026 Protocolado em 14 de jan. de 2026Alam Kamran Officer: CHIEF FINANCIAL OFFICER
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Valor mobiliário derivativo: Employee Stock Option (right to buy) — subjacente Common Stock (231.000) — preço de exercício 4.86
Adquirido (A)231.0000—231.000Direta (D) Não
F2
  • F2 25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir documento 0001793412-26-000002 Lido do XML do documento Contestar esta linha
1 de dez. de 2025 Protocolado em 1 de dez. de 2025Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Adquirido (A)260.0471,71
444.680,37

Derivado: ações × preço por ação. Valor exato 444680.37.

1.266.486Direta (D) Não— Abrir documento 0001665124-25-000003 Lido do XML do documento Contestar esta linha
1 de dez. de 2025 Protocolado em 1 de dez. de 2025Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Alienado (D)260.0474,51
1.172.811,97

Derivado: ações × preço por ação. Valor exato 1172811.97.

1.006.439Direta (D) Não
F2
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.42 to $4.63 inclusive.
Abrir documento 0001665124-25-000003 Lido do XML do documento Contestar esta linha
1 de dez. de 2025 Protocolado em 1 de dez. de 2025Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Valor mobiliário derivativo: Employee Stock Option (right to buy) — subjacente Common Stock (260.047) — preço de exercício 1.71
Alienado (D)260.0470—563.617Direta (D) Não
F4
  • F4 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir documento 0001665124-25-000003 Lido do XML do documento Contestar esta linha
28 de nov. de 2025 Protocolado em 1 de dez. de 2025Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Adquirido (A)70.1720,6989
49.043,2108

Derivado: ações × preço por ação. Valor exato 49043.2108.

1.076.611Direta (D) Não— Abrir documento 0001665124-25-000003 Lido do XML do documento Contestar esta linha
28 de nov. de 2025 Protocolado em 1 de dez. de 2025Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Adquirido (A)39.9531,71
68.319,63

Derivado: ações × preço por ação. Valor exato 68319.63.

1.116.564Direta (D) Não— Abrir documento 0001665124-25-000003 Lido do XML do documento Contestar esta linha
28 de nov. de 2025 Protocolado em 1 de dez. de 2025Nagendran Sukumar Director · Officer: President and Head of RD
S

Open market or private sale of non-derivative or derivative security

Common Stock
Alienado (D)110.1254,75
523.093,75

Derivado: ações × preço por ação. Valor exato 523093.75.

1.006.439Direta (D) Não
F1
  • F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.7248 to $4.8348 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2).
Abrir documento 0001665124-25-000003 Lido do XML do documento Contestar esta linha
28 de nov. de 2025 Protocolado em 1 de dez. de 2025Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Valor mobiliário derivativo: Employee Stock Option (right to buy) — subjacente Common Stock (70.172) — preço de exercício 0.6989
Alienado (D)70.1720—222.683Direta (D) Não
F3
  • F3 The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir documento 0001665124-25-000003 Lido do XML do documento Contestar esta linha
28 de nov. de 2025 Protocolado em 1 de dez. de 2025Nagendran Sukumar Director · Officer: President and Head of RD
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Valor mobiliário derivativo: Employee Stock Option (right to buy) — subjacente Common Stock (39.953) — preço de exercício 1.71
Alienado (D)39.9530—823.664Direta (D) Não
F4
  • F4 25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
Abrir documento 0001665124-25-000003 Lido do XML do documento Contestar esta linha

Detentores institucionais (Formulário 13F)

Nenhuma posição do Formulário 13F está ligada a este emissor no repositório. Um detentor ainda não vinculado ou que ainda não entregou está ausente, não em zero.

Detentores de 5 % (Schedules 13D e 13G)

Aqui são lidos os schedules entregues no formato estruturado da SEC (desde o fim de 2024). Os anteriores são texto livre e não são lidos.

Detentores de 5 %, evento mais recente primeiro, conforme entregue
DetentorPercentual da classeAções detidasData do eventoFormulárioFonte
RA Capital Management, L.P. Common Stock, $0.00001 par value per share9.932.886.242,0006/30/2026 Protocolado em 14 de ago. de 2026SCHEDULE 13G/AEmenda 5Abrir documento 0001231919-26-000928 Contestar esta linha
Peter Kolchinsky Common Stock, $0.00001 par value per share9.932.886.242,0006/30/2026 Protocolado em 14 de ago. de 2026SCHEDULE 13G/AEmenda 5Abrir documento 0001231919-26-000928 Contestar esta linha
Rajeev Shah Common Stock, $0.00001 par value per share9.932.886.242,0006/30/2026 Protocolado em 14 de ago. de 2026SCHEDULE 13G/AEmenda 5Abrir documento 0001231919-26-000928 Contestar esta linha
RA Capital Healthcare Fund, L.P. Common Stock, $0.00001 par value per share9.932.886.242,0006/30/2026 Protocolado em 14 de ago. de 2026SCHEDULE 13G/AEmenda 5Abrir documento 0001231919-26-000928 Contestar esta linha
Morgan Stanley Common Stock5.116.244.33906/30/2026 Protocolado em 13 de ago. de 2026SCHEDULE 13G/AEmenda 2Abrir documento 0000895421-26-000269 Contestar esta linha
Morgan Stanley Capital Services LLC Common Stock5.016.001.13006/30/2026 Protocolado em 13 de ago. de 2026SCHEDULE 13G/AEmenda 2Abrir documento 0000895421-26-000269 Contestar esta linha
Vestal Point Capital, LP Common Stock, par value $0.00001 per share6.318.000.000,0003/31/2026 Protocolado em 15 de mai. de 2026SCHEDULE 13G/AEmenda 1Abrir documento 0000902664-26-002553 Contestar esta linha
Ryan Wilder Common Stock, par value $0.00001 per share6.318.000.000,0003/31/2026 Protocolado em 15 de mai. de 2026SCHEDULE 13G/AEmenda 1Abrir documento 0000902664-26-002553 Contestar esta linha
RTW Investments, LP Common Stock, par value $0.00001 per share7.020.689.084,0003/31/2026 Protocolado em 15 de mai. de 2026SCHEDULE 13G/AEmenda 5Abrir documento 0001493215-26-000122 Contestar esta linha
Roderick Wong Common Stock, par value $0.00001 per share7.020.689.084,0003/31/2026 Protocolado em 15 de mai. de 2026SCHEDULE 13G/AEmenda 5Abrir documento 0001493215-26-000122 Contestar esta linha
RTW Investments, LP Common Stock, par value $0.00001 per share8.323.407.133,0012/31/2025 Protocolado em 17 de fev. de 2026SCHEDULE 13G/AEmenda 4Abrir documento 0001493215-26-000050 Contestar esta linha
Roderick Wong Common Stock, par value $0.00001 per share8.323.407.133,0012/31/2025 Protocolado em 17 de fev. de 2026SCHEDULE 13G/AEmenda 4Abrir documento 0001493215-26-000050 Contestar esta linha
Vestal Point Capital, LP Common Stock, par value $0.00001 per share513.750.000,0012/31/2025 Protocolado em 17 de fev. de 2026SCHEDULE 13GAbrir documento 0000902664-26-001081 Contestar esta linha
Ryan Wilder Common Stock, par value $0.00001 per share513.750.000,0012/31/2025 Protocolado em 17 de fev. de 2026SCHEDULE 13GAbrir documento 0000902664-26-001081 Contestar esta linha
FMR LLC COMMON STOCK4.913.528.365,8712/31/2025 Protocolado em 5 de fev. de 2026SCHEDULE 13G/AEmenda 10Abrir documento 0000315066-26-000536 Contestar esta linha
Abigail P. Johnson COMMON STOCK4.913.528.365,8712/31/2025 Protocolado em 5 de fev. de 2026SCHEDULE 13G/AEmenda 10Abrir documento 0000315066-26-000536 Contestar esta linha
BlackRock, Inc. Common Stock6.517.852.29112/31/2025 Protocolado em 21 de jan. de 2026SCHEDULE 13G/AEmenda 2Abrir documento 0002012383-26-000794 Contestar esta linha
RA Capital Management, L.P. Common Stock, $0.00001 par value per share9.927.662.481,0009/30/2025 Protocolado em 14 de nov. de 2025SCHEDULE 13G/AEmenda 4Abrir documento 0001231919-25-000491 Contestar esta linha
Peter Kolchinsky Common Stock, $0.00001 par value per share9.927.662.481,0009/30/2025 Protocolado em 14 de nov. de 2025SCHEDULE 13G/AEmenda 4Abrir documento 0001231919-25-000491 Contestar esta linha
Rajeev Shah Common Stock, $0.00001 par value per share9.927.662.481,0009/30/2025 Protocolado em 14 de nov. de 2025SCHEDULE 13G/AEmenda 4Abrir documento 0001231919-25-000491 Contestar esta linha
RA Capital Healthcare Fund, L.P. Common Stock, $0.00001 par value per share9.927.662.481,0009/30/2025 Protocolado em 14 de nov. de 2025SCHEDULE 13G/AEmenda 4Abrir documento 0001231919-25-000491 Contestar esta linha
Octagon Capital Advisors LP Common Stock, $0.00001 par value3.39.067.500,0009/30/2025 Protocolado em 14 de nov. de 2025SCHEDULE 13G/AEmenda 1Abrir documento 0001214659-25-016718 Contestar esta linha
Octagon Investments Master Fund Common Stock, $0.00001 par value3.39.067.500,0009/30/2025 Protocolado em 14 de nov. de 2025SCHEDULE 13G/AEmenda 1Abrir documento 0001214659-25-016718 Contestar esta linha
Ting Jia Common Stock, $0.00001 par value3.39.067.500,0009/30/2025 Protocolado em 14 de nov. de 2025SCHEDULE 13G/AEmenda 1Abrir documento 0001214659-25-016718 Contestar esta linha
RA Capital Management, L.P. Common Stock, $0.00001 par value per share9.925.345.988,0006/30/2025 Protocolado em 14 de ago. de 2025SCHEDULE 13G/AEmenda 3Abrir documento 0001415889-25-022033 Contestar esta linha
Peter Kolchinsky Common Stock, $0.00001 par value per share9.925.345.988,0006/30/2025 Protocolado em 14 de ago. de 2025SCHEDULE 13G/AEmenda 3Abrir documento 0001415889-25-022033 Contestar esta linha
Rajeev Shah Common Stock, $0.00001 par value per share9.925.345.988,0006/30/2025 Protocolado em 14 de ago. de 2025SCHEDULE 13G/AEmenda 3Abrir documento 0001415889-25-022033 Contestar esta linha
RA Capital Healthcare Fund, L.P. Common Stock, $0.00001 par value per share9.925.345.988,0006/30/2025 Protocolado em 14 de ago. de 2025SCHEDULE 13G/AEmenda 3Abrir documento 0001415889-25-022033 Contestar esta linha
RTW Investments, LP Common Stock, par value $0.00001 per share9.925.183.287,0006/30/2025 Protocolado em 14 de ago. de 2025SCHEDULE 13G/AEmenda 3Abrir documento 0001415889-25-021712 Contestar esta linha
Roderick Wong Common Stock, par value $0.00001 per share9.925.183.287,0006/30/2025 Protocolado em 14 de ago. de 2025SCHEDULE 13G/AEmenda 3Abrir documento 0001415889-25-021712 Contestar esta linha
FMR LLC COMMON STOCK6.215.627.821,8706/30/2025 Protocolado em 6 de ago. de 2025SCHEDULE 13G/AEmenda 9Abrir documento 0000315066-25-002098 Contestar esta linha
Abigail P. Johnson COMMON STOCK6.215.627.821,8706/30/2025 Protocolado em 6 de ago. de 2025SCHEDULE 13G/AEmenda 9Abrir documento 0000315066-25-002098 Contestar esta linha
Morgan Stanley Common Stock6.716.858.64406/30/2025 Protocolado em 6 de ago. de 2025SCHEDULE 13G/AEmenda 1Abrir documento 0000895421-25-000463 Contestar esta linha
Morgan Stanley Capital Services LLC Common Stock5.614.095.14306/30/2025 Protocolado em 6 de ago. de 2025SCHEDULE 13G/AEmenda 1Abrir documento 0000895421-25-000463 Contestar esta linha
BlackRock, Inc. Common Stock5.213.153.32606/30/2025 Protocolado em 16 de jul. de 2025SCHEDULE 13G/AEmenda 1Abrir documento 0002052113-25-002549 Contestar esta linha
THE GOLDMAN SACHS GROUP, INC. Common Stock, par value $0.00001 per share5.112.748.968,0006/26/2025 Protocolado em 3 de jul. de 2025SCHEDULE 13GAbrir documento 0000769993-25-000401 Contestar esta linha
GOLDMAN SACHS CO. LLC Common Stock, par value $0.00001 per share5.112.748.968,0006/26/2025 Protocolado em 3 de jul. de 2025SCHEDULE 13GAbrir documento 0000769993-25-000401 Contestar esta linha

O percentual é da classe indicada no documento, como declarado pelo detentor. Os membros de um grupo informam cada um as ações do grupo, por isso as linhas não se somam.

O que foi lido

2.093.437 documentos lidos, de 14 de jun. de 2004 a 13 de nov. de 2026: Formulários 3, 3/A, 4, 4/A, 5, 5/A.

Alguns anos podem estar incompletos enquanto o arquivo ainda é lido. Um ano com poucos documentos aqui não afirma que poucos foram entregues.

Documentos lidos, por ano de entrega
Ano de entregaDocumentos lidos
20151
2016204.322
2017202.494
2018202.048
2019193.638
2020144.184
2021224.474
202240.015
2023199.811
2024186.415
2025235.520
2026254.737

Os documentos anteriores à exigência de XML pela SEC são listados, mas não extraídos.

Voltar para Taysha Gene Therapies, Inc.